Advertisement

Thirty-day readmission rate of same-day discharge protocol after left atrial appendage occlusion: A propensity score–matched analysis from the National Readmission Database

      Background

      Given the reduction in periprocedural complication rates, same-day discharge (SDD) after percutaneous left atrial appendage closure (LAAC) could be beneficial. To date, little data exist comparing the standard overnight stay (ONS) vs SDD after LAAC.

      Objective

      The purpose of this study was to investigate the safety and efficacy of SDD compared with ONS.

      Methods

      A retrospective cohort study of LAAC procedures performed in the United States from 2015 to 2019 was conducted using the US Nationwide Readmission Database. The primary outcome was all-cause 30-day readmission after discharge in patients who underwent LAAC, and a secondary outcome was requiring total health care cost. A 1:1 propensity score matching was conducted for adjustment. Multivariate Cox proportional hazards regression was also performed to estimate the hazard ratio for all-cause readmission within 30 days of LAAC.

      Results

      Of 48,953 patients (mean age 76.0 ± 7.9 years), 972 patients (1.99%) were discharged on the same day after LAAC (SDD group) and the remaining 47,981 patients stayed at least 1 night (ONS group). A propensity score–matched analysis generated 961 matched pairs in each group. The 30-day readmission rate after discharge was similar between the groups (SDD vs ONS: 8.5% vs 9.8%; P = .31; hazard ratio 1.13; 95% confidence interval 0.78–1.63; P = .53). The total required health care cost was significantly lower in the SDD group ($23,720 [$18,075–$29,416] vs $25,877 [$19,906–$32,748]; P < .01). Gastrointestinal bleeding was the major cause for readmission (SDD vs ONS: 14.7% vs 15.1%; P = .95), but stroke and pericardial effusion were rare.

      Conclusion

      In patients without procedure-related complications, SDD is a safe and cost-effective protocol.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Benjamin E.J.
        • Muntner P.
        • Alonso A.
        • et al.
        Heart Disease and Stroke Statistics—2019 update: a report from the American Heart Association.
        Circulation. 2019; 139: e56-e528
        • January C.T.
        • Wann L.S.
        • Calkins H.
        • et al.
        2019 AHA/ACC/HRS focused update of the 2014 AHA/ ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
        J Am Coll Cardiol. 2019; 74: 104-132
        • O’Brien E.C.
        • Holmes D.N.
        • Ansell J.E.
        • et al.
        Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
        Am Heart J. 2014; 167: 601-609.e1
        • Holmes D.R.
        • Reddy V.Y.
        • Turi Z.G.
        • et al.
        Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.
        Lancet. 2009; 374: 534-542
        • Holmes Jr., D.R.
        • Kar S.
        • Price M.J.
        • et al.
        Prospective randomized evaluation of the WATCHMAN left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
        J Am Coll Cardiol. 2014; 64: 1-12
        • Boersma L.V.
        • Schmidt B.
        • Betts T.R.
        • et al.
        EWOLUTION Investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry.
        Eur Heart J. 2016; 37: 2465-2474
        • Freeman J.V.
        • Varosy P.
        • Price M.J.
        • et al.
        The NCDR left atrial appendage occlusion registry.
        J Am Coll Cardiol. 2020; 75: 1503-1518
        • Sahashi Y.
        • Kuno T.
        • Tanaka Y.
        • Passman R.
        • Briasoulis A.
        • Malik A.H.
        The 30-day readmission rate of same-day discharge protocol following catheter ablation for atrial fibrillation: a propensity score-matched analysis from National Readmission Database.
        Europace. 2022; 24: 755-761
        • Gilhofer T.S.
        • Inohara T.
        • Parsa A.
        • et al.
        Safety and feasibility of same-day discharge after left atrial appendage closure.
        Can J Cardiol. 2020; 36: 945-947
        • Marmagkiolis K.
        • Ates I.
        • Kose G.
        • Iliescu C.
        • Cilingiroglu M.
        Effectiveness and safety of same day discharge after left atrial appendage closure under moderate conscious sedation.
        Catheter Cardiovasc Interv. 2021; 97: 912-916
        • Tan B.E.
        • Boppana L.K.T.
        • Abdullah A.S.
        • et al.
        Safety and feasibility of same-day discharge after left atrial appendage closure with the WATCHMAN device.
        Circ Cardiovasc Interv. 2021; 14e009669
        • Healthcare Cost & Utilization Project: User Support
        Overview of the Nationwide Readmissions Database (NRD). Agency for Healthcare Research and Quality (AHRQ) Web site.
        https://www.hcup-us.ahrq.gov/nrdoverview.jsp
        Date accessed: December 22, 2021
        • Knottnerus A.
        • Tugwell P.
        STROBE—a checklist to Strengthen the Reporting of Observational Studies in Epidemiology.
        J Clin Epidemiol. 2008; 61: 323
        • Freeman J.V.
        • Varosy P.
        • Price M.J.
        • et al.
        The NCDR Left Atrial Appendage Occlusion Registry.
        J Am Coll Cardiol. 2020; 75: 1503-1518
        • Calkins H.
        • Hindricks G.
        • Cappato R.
        2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.
        Heart Rhythm. 2017; 14: e275-e444
        • Darden D.
        • Duong T.
        • Du C.
        • et al.
        Sex differences in procedural outcomes among patients undergoing left atrial appendage occlusion: insights from the NCDR LAAO Registry.
        JAMA Cardiol. 2021; 6: 1275-1284
      1. State health facts: hospital adjusted expenses per inpatient day.
        2018. KFF Web site. 2018;
        • Abdelaal E.
        • Rao S.V.
        • Gilchrist I.C.
        • et al.
        Same-day discharge compared with overnight hospitalization after uncomplicated percutaneous coronary intervention: a systematic review and meta-analysis.
        JACC Cardiovasc Interv. 2013; 6: 99-112
        • WATCHMAN left atrial appendage (LAA) closure technology
        Premarket approval (PMA) number P130013. U.S. Food & Drug Administration Web site.
        • Kar S.
        • Doshi S.K.
        • Sadhu A.
        • et al.
        Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial.
        Circulation. 2021; 143: 1754-1762